Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference
12 Outubro 2022 - 8:30AM
Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or
the “Company”), a leader in novel serotonergic psychedelic drug
development committed to innovating proprietary therapeutic
solutions for mental health conditions, announced today that the
Company’s President and CEO, Mr. Greg Mayes, will participate on a
panel at this year’s Horizons Perspectives on Psychedelics
conference, taking place at the New York Academy of Medicine in New
York City.
The panel session, titled, “Raising Capital for
Psychedelic Endeavors,” is part of the conference’s Psychedelic
Business Forum and will focus on how both companies and funds are
raising capital to expand their business interests in the growing
field of psychedelic medicine. The panel will take place on
Thursday, Oct. 13, 2022, at 2:30 p.m. ET.
“There is a clear and urgent need to address the
ongoing mental health crisis that plagues society today, and
science has proven that psychedelic medicine may be key to
developing the next generation of effective CNS treatments,” said
Mr. Mayes. “As such, it is vital that we think about psychedelics
as an important component to mental health treatment in much the
same way that we evaluate the use of traditional therapeutics. The
evidence supporting the success of psychedelic treatment across a
wide range of psychiatric conditions continues to evolve, and these
promising therapies deserve both attention and investment. This is
an important conversation to have to set the record straight, and I
look forward to exploring this topic more in-depth at Horizons to
further raise awareness.”
Presented by Horizons PBC, a public benefit
corporation, the Perspectives on Psychedelics conference is the
largest and longest-running annual gathering of the psychedelic
community in the world. Its Psychedelic Business Forum explores the
psychedelic economy and industry for executives, entrepreneurs and
funders.
About Reunion Neuroscience Inc.,
(formerly, Field Trip Health Ltd.)Reunion is a leader in
novel psychedelic drug development, committed to innovating
therapeutic solutions for mental health conditions by developing
proprietary serotonin receptor agonist compounds. The Company’s
lead asset, RE-104 (previously known as FT-104), is a proprietary,
novel serotonergic psychedelic drug being developed for post-partum
and treatment resistant depression as a potential fast-acting
antidepressant with durable efficacy. Reunion is also developing
the FT-200 series, which includes compounds with potential for more
selective serotonin receptor activity with reduced psychoactivity
for potential use in more chronic treatment paradigms and
indications.
Learn more at
https://www.investors.reunionneuro.com, and
https://www.reunionneuro.com.
Follow us on LinkedIn, Twitter and
Instagram.
To be added to the Reunion Neuroscience email
list, please email Reunion@kcsa.com with “REUN” in the subject
line.
Cautionary Note Regarding
Forward-Looking Information This release
includes forward-looking information (within the meaning of
Canadian securities laws and within the meaning of the United
States Private Securities Litigation Reform Act of 1995) regarding
the Company and its business. Often but not always, forward-looking
information can be identified by the use of words such as "expect",
"intends", "anticipated", "believes" or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results "may", "could", "would" or
"will" be taken, occur or be achieved. Such statements are based on
the current expectations and views of future events of the
management of the Company and are based on assumptions and subject
to risks and uncertainties. Although the management of believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and the
Company does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise. Additional information
relating to Field Trip, including its Annual Information Form, can
be located on the SEDAR website at www.sedar.com and on the EDGAR
section of the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Media Contact:Shana Marino KCSA Strategic
Communications(347) 487-6189reunion@kcsa.com
Investor Contacts:Phil Carlson / Sophia
BashfordKCSA Strategic Communications(646) 573-0776 / (929)
246-7307reunion@kcsa.com
Reunion Neuroscience (TSX:REUN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Reunion Neuroscience (TSX:REUN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024